The first patient has been dosed in a phase 1 clinical trial evaluating EYP-1901 for the treatment of wet age-related macular degeneration, according to a press release from EyePoint Pharmaceuticals.
DAVIO is an open-label, dose-escalation trial investigating EYP-1901 (Durasert sustained-release technology with vorolanib) in 13 patients with wet AMD who were responsive to previous anti-VEGF treatments. The insert has the potential to offer a twice-yearly sustained delivery treatment for wet AMD.
“The potential efficacy of vorolanib coupled with the well-characterized safety and
Uncategorized